A connection you can count on.

Egetis RareLink™ Copay Card Program Terms and Conditions

• Patients must be enrolled in Egetis RareLink™ and have a valid prescription for Emcitate^® (tiratricol) for an FDA-approved indication.
• Patients must live in and receive treatment in the United States or Puerto Rico, Guam, or the US Virgin Islands, and meet program eligibility requirements.
• Available only to eligible patients with private or commercial insurance coverage for Emcitate^® (tiratricol). The program is not valid for uninsured patients or for patients covered, in whole or in part, by any federal or state healthcare program.
• Not valid for patients enrolled in Medicare, Medicaid, TRICARE, CHAMPUS, VA, DoD, Puerto Rico Government Health Insurance Plan, or any other federal or state medical or pharmaceutical benefit program.
• Copay assistance applies only to eligible out-of-pocket costs for Emcitate^® (tiratricol) and may not be used for office visits, laboratory testing, administration fees, or other services or products.
• Program benefits may be subject to annual maximums, claim limits, documentation requirements, and other restrictions established by Egetis.
• Patient, caregiver, pharmacy, or healthcare provider may be responsible for any remaining out-of-pocket costs after copay assistance is applied.
• By participating, the patient, caregiver, pharmacy, and healthcare provider agree not to seek reimbursement from any insurer, health plan, government program, or other third party for any benefit received through the copay assistance program, except as required by law.
• The copay assistance program is not insurance and is void where prohibited by law, taxed, or restricted. The offer is not transferable, cannot be combined with any other copay card, discount, free trial, prescription savings card, or similar offer, and cannot be redeemed for cash.
• If a patient’s insurance status changes, the patient or caregiver should notify Egetis RareLink™ as soon as possible, as eligibility for copay assistance may change.
• Egetis reserves the right to rescind, revoke, amend, or discontinue the copay assistance program or these terms and conditions at any time without notice.

©2026, Egetis Therapeutics US, Inc. EMCITATE is a trademark owned by Rare Thyroid Therapeutics International AB, an Egetis Therapeutics AB company. Egetis Therapeutics and Egetis RareLink are trademarks owned by Egetis Therapeutics US, Inc.

All rights reserved. US-TIRA-2600077 2026-09